Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2014

Open Access 01-12-2014 | Research article

Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression

Authors: Sokratis E Karaoulanis, Katerina A Rizouli, Andreas A Rizoulis, Nikiforos V Angelopoulos

Published in: BMC Psychiatry | Issue 1/2014

Login to get access

Abstract

Background

Major depression is associated with higher plasma levels of positive acute-phase proteins, as well as with lower plasma levels of negative acute-phase proteins. The aim of this study is to examine the levels of acute-phase response proteins and whether these levels are influenced by reproductive hormones and antidepressant medication in the perimenopausal depression.

Methods

Sixty-five women (age range: 40–58 years old) participated in this study. All women were in the perimenopausal phase. The diagnosis of depression was made through a psychiatric interview and with the aid of Hamilton Depression Rating Scale 17 (HAM-D 17). The acute-phase response proteins, such as haptoglobin (HP), transferrine (TRf), α1-antitrypsin, complement protein 3 (C3), complement protein 4 (C4) and C-reactive protein (CRP) and the reproductive hormones, for example follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2), were analyzed using standard laboratory methods. Pearson’s correlations were applied to evaluate the relationship between acute-phase proteins and hormones.

Results

Perimenopausal women were divided into three groups. The first group consisted of normal controls, the second one involved depressed perimenopausal women, who were taking selective serotonin reuptake inhibitors (SSRIs), and the third one included depressed women that were not treated with SSRIs. Depressed women in perimenopause, when being compared to non-depressed women, did not differ as to serum levels of acute-phase proteins. There was a positive correlation between HP and E2 in depressed perimenopausal women, who were not taking SSRIs.

Conclusions

The lack of association between acute-phase proteins and depressive mood mentioned in this study does not support previous findings in patients with major depression. This negative finding in perimenopausal depression indicates either the absence or a more complex nature of the interactions between acute-phase proteins, low-grade inflammation and depression. The hormonal profile of women is a part of this complexity, because it seems that in perimenopause the hormonal changes are accompanied by changes of acute-phase response proteins. Particularly, in perimenopausal depression, there is an interaction between HP and E2. Therefore, it seems that perimenopause is a period of a woman’s life during which hormonal, immune and metabolic changes occur and interact with each other making women vulnerable to depression.
Appendix
Available only for authorised users
Literature
1.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010, 67: 446-457. 10.1016/j.biopsych.2009.09.033.CrossRefPubMed
2.
Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1 and IL-6: a meta-analysis. Psychosom Med. 2009, 71: 171-186. 10.1097/PSY.0b013e3181907c1b.CrossRefPubMed
3.
Maes M: Evidence for an immune response in major depression: a review and major hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995, 19: 11-38. 10.1016/0278-5846(94)00101-M.CrossRefPubMed
4.
Wium-Andersen MK, Orsted DD, Nielsen SF, Nordestgaard BG: Elevated C-reactive protein levels, psychological distress and depression in 73.131 individuals. JAMA Psychiatry. 2013, 70 (2): 176-184. 10.1001/2013.jamapsychiatry.102.CrossRefPubMed
5.
Ford DE, Erlinger TP: Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004, 164 (9): 1010-1014. 10.1001/archinte.164.9.1010.CrossRefPubMed
6.
Danner M, Kasl SV, Abramson JL, Vaccarino V: Association between depression and elevated C-reactive protein. Psychosom Med. 2003, 65 (3): 347-356. 10.1097/01.PSY.0000041542.29808.01.CrossRefPubMed
7.
Legros S, Mendlewicz , Wybran J: Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 1985, 235: 9-11. 10.1007/BF00380962.CrossRef
8.
Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Cytokine production and serum proteins in depression. Scand J Immunol. 1995, 41: 534-538. 10.1111/j.1365-3083.1995.tb03604.x.CrossRefPubMed
9.
Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K: Indicators of immune activation in major depression. Psychiatry Res. 1996, 64: 161-167. 10.1016/S0165-1781(96)02783-7.CrossRefPubMed
10.
Sluzewska A, Rybakowski J, Sobieska M, Wiktorowicz K: Concentration and microheterogeneity glycophorms of a1-acid glycoprotein in major depressive disorder. J Affect Disord. 1996, 39: 149-155. 10.1016/0165-0327(96)00026-2.CrossRefPubMed
11.
Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A: Acute phase proteins in major depression. J Psychosom Res. 1997, 43: 529-534. 10.1016/S0022-3999(97)00139-6.CrossRefPubMed
12.
Douglas KM, Taylor AJ, O’Malley PG: Relationship between depression and C- reactive protein in a screening population. Psychosom Med. 2004, 66 (5): 679-683. 10.1097/01.psy.0000138132.66332.85.CrossRefPubMed
13.
Joyce PRHCR, Mulder RT, Sellman JD, Willson DA, Boswell DR: Elevated levels of acute phase proteins in major depression. Biol Psychiatry. 1992, 32: 1035-1041. 10.1016/0006-3223(92)90065-8.CrossRefPubMed
14.
Maes M, Scharpe S, Bosmans E, Vandewoude M, Suy E, Uyttenbroeck W, Cooreman W, Vandervorst C, Raus J: Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry. 1992, 16: 501-515. 10.1016/0278-5846(92)90056-K.CrossRefPubMed
15.
Zorilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorcle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001, 15: 199-226. 10.1006/brbi.2000.0597.CrossRef
16.
Maes M, Scharpe S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P, Suy B: Higher alpha-1 antitrypsin, haptoglobin, seruloplasmin and lower retinal binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord. 1992, 24: 183-192. 10.1016/0165-0327(92)90066-F.CrossRefPubMed
17.
Maes M, Scharpe S, Meltzer HY, Cosyns P: Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol Psychiatry. 1993, 34: 690-701. 10.1016/0006-3223(93)90042-C.CrossRefPubMed
18.
Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P: Relationships between interleukin-6 activity, acute phase proteins and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993, 49: 11-27. 10.1016/0165-1781(93)90027-E.CrossRefPubMed
19.
Maes M, Delanghe J, Scharpe S, Meltzer HY, Cosyns P, Suy E, Bosmans E: Haptoglobin phenotypes and gene frequencies in unipolar major depression. Am J Psychiatry. 1994, 151: 112-116.CrossRefPubMed
20.
Maes M, Delanghe J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S: Aute phase proteins in schizophrenia, mania and major depression modulation by psychotropic drugs. Psychiatry Res. 1997, 66: 1-11. 10.1016/S0165-1781(96)02915-0.CrossRefPubMed
21.
Song C, Dinan T, Leonard BE: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord. 1994, 30: 283-288. 10.1016/0165-0327(94)90135-X.CrossRefPubMed
22.
Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW: Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. 2013, 18 (6): 692-699. 10.1038/mp.2012.144.CrossRefPubMed
23.
Maes M, Bosmans E, Suy E, Minner B, Raus J: Immune cell parameters in severely depressed patients: negative findings. J Affect Disord. 1989, 17: 121-128. 10.1016/0165-0327(89)90034-7.CrossRefPubMed
24.
Maes M, Meltzer HY, Stevens W, Calabrese J, Cosyns P: Natural killer cell activity in major depression: relation to circulating natural killer cells. Cellular indices of the immune response, and depressive phenomenology. Prog Neuropsychopharmacol Biol Psychiatry. 1994, 18: 717-730. 10.1016/0278-5846(94)90079-5.CrossRefPubMed
25.
Maes M, Meltzer HY, Scharpe S, Cooreman W, Uyttenbroeck W, Suy E, Vandervorst C, Calabrese J, Raus J, Cosyns P: Psychomotor retardation, anorexia, weight loss, sleep disturbances and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res. 1993, 47: 229-241. 10.1016/0165-1781(93)90081-Q.CrossRefPubMed
26.
Mc Adams C, Leonard BE: Neutrophil and monocyte phagocytosis in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 1993, 17: 971-984. 10.1016/0278-5846(93)90024-M.CrossRef
27.
Seidel A, Arolt V, Hunstiger M, Rink L, Bechnisch A, Kirchner H: Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand. 1996, 94 (3): 198-204. 10.1111/j.1600-0447.1996.tb09849.x.CrossRefPubMed
28.
Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, Kirchner H: Inflammatory markers in major depression and melancholia. J Affect Disord. 2001, 63: 93-102. 10.1016/S0165-0327(00)00157-9.CrossRefPubMed
29.
Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS: Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause. The Harvard Study of Mood and Cycles. Arch Gen Psychiatry. 2003, 60: 29-36. 10.1001/archpsyc.60.1.29.CrossRefPubMed
30.
Schmidt PJ, Murphy JH, Haq N, Rubinow DR, Danaceau MA: Stressful life events, personal losses and perimenopause related depression. Arch Womens Ment health. 2004, 7 (1): 19-26. 10.1007/s00737-003-0036-2.CrossRefPubMed
31.
Freeman EW, Sammel M, Liu L, Gracia CR, Nelson DB, Hollander L: Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004, 61: 62-70. 10.1001/archpsyc.61.1.62.CrossRefPubMed
32.
Freeman EW, Sammel MD, Lin H, Nelson DB: Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006, 63: 375-382. 10.1001/archpsyc.63.4.375.CrossRefPubMed
33.
Freeman EW: Associations of depression with the transition to menopause. Menopause. 2010, 17 (4): 823-827. 10.1097/gme.0b013e3181db9f8b.CrossRefPubMed
34.
Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999, 100: 717-722. 10.1161/01.CIR.100.7.717.CrossRefPubMed
35.
Dreon DM, Slavin JL, Phinney SD: Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci. 2003, 73: 1245-1252. 10.1016/S0024-3205(03)00425-9.CrossRefPubMed
36.
Jilma B, Dimberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG, Kapiotis S, Wagner OF: Menstrual cycle associated changes in blood levels of interleukin-6, alpha 1 acid glucoprotein and C-reactive protein. J Lab Clin Med. 1997, 130: 69-75. 10.1016/S0022-2143(97)90060-3.CrossRefPubMed
37.
Ozturk O, Eraslan D, Mete HE, Ozsener S: The risk factors and symptomatology of perimenopausal depression. Maturitas. 2006, 55 (2): 180-186. 10.1016/j.maturitas.2006.02.001.CrossRefPubMed
38.
Karaoulanis SE, Daponte A, Rizouli KA, Rizoulis AA, Lialios GA, Theodoridou CT, Christakopoulos C, Angelopoulos NV: The role of cytokines and hot flashes in perimenopausal depression. Annal Gen Psychiatry. 2012, 11: 9-10.1186/1744-859X-11-9.CrossRef
39.
Ushiroyama T, Ikeda A, Ueki M: Elevated plasma interleukin 6 (IL-6) and soluble IL-6 receptor concentrations in menopausal women with and without depression. Int J Gynecol Obstet. 2002, 79: 51-52. 10.1016/S0020-7292(02)00189-3.CrossRef
40.
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003, 289: 2651-2662. 10.1001/jama.289.20.2651.CrossRefPubMed
41.
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004, 291: 2947-2958. 10.1001/jama.291.24.2947.CrossRefPubMed
42.
Brinton RD: Investigative models for determining hormone therapy-induced outcomes in brain. Evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci. 2005, 1052: 57-74. 10.1196/annals.1347.005.CrossRefPubMed
43.
Chang YC, Tzeng SF, Yu L, Huang AM, Lee HT, Huang CC, Ho CJ: Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiol Dis. 2006, 24: 101-113. 10.1016/j.nbd.2006.06.001.CrossRefPubMed
44.
Li IH, Huang WS, Shiue CY, Huang YY, Liu RS, Chyueh SC, Hu SH, Liao MH, Shen LH, Liu JC, Ma KH: Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET. Neuroimage. 2010, 49: 1259-1270. 10.1016/j.neuroimage.2009.07.072.CrossRefPubMed
45.
Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, Yoon SH, Lee JK: Fluoxetine attenuates kainic acid induced neuronal cell death in the mouse hippocampus. Brain Res. 2009, 1281: 108-116.CrossRefPubMed
46.
Chen SJ, Kao CL, Chang YL, Yen CJ, Shui JW, Chien CS, Chen IL, Tsai TH, Ku HH, Chiou SH: Anti depressant administration modulates neural stem cell survival and serotoninergic differentiation through bcl-2. Curr Neurovasc Res. 2007, 4: 19-29. 10.2174/156720207779940707.CrossRefPubMed
47.
Zhang F, Zhou H, Wilson BL, Shi JS, Hong JS, Gao HM: Fluoxetine protect neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord. 2012, 18S1: S213-S217.CrossRef
48.
Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK: Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009, 87: 1037-1045. 10.1002/jnr.21899.CrossRefPubMed
49.
Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, Duman RS: Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci. 2002, 22: 3673-3682.PubMed
50.
Taler M, Miron O, Gil-Ad I, Weizman A: Neurocognitive and procognitive effects of sertraline: In vitro and in vivo studies. Neurosci Lett. 2013, 550: 93-97.CrossRefPubMed
51.
Erdem M, Celic C, Cayci T, Ozderim B, Kurt YG, Akgul EO, Yaman H, Balikci A, Uzun O: Serum haptoglobin levels in patients with melancholic and nonmelancholic major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011, 35: 944-947. 10.1016/j.pnpbp.2011.01.009.CrossRef
52.
Metadata
Title
Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression
Authors
Sokratis E Karaoulanis
Katerina A Rizouli
Andreas A Rizoulis
Nikiforos V Angelopoulos
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2014
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-14-164

Other articles of this Issue 1/2014

BMC Psychiatry 1/2014 Go to the issue

Research article

Prevalence of psychiatric symptoms in children and adolescents one year after the 2009 L'Aquila earthquake

Research article

Clinical and sociodemographic correlates of suicidality in patients with major depressive disorder from six Asian countries

Research article

Effects of mental health self-efficacy on outcomes of a mobile phone and web intervention for mild-to-moderate depression, anxiety and stress: secondary analysis of a randomised controlled trial

Debate

Etiological classification of depression based on the enzymes of tryptophan metabolism

Research article

Validity of subjective versus objective quality of life assessment in people with schizophrenia

Research article

Association of serum leptin and ghrelin with depressive symptoms in a Japanese working population: a cross-sectional study